Investor Relations Contacts

Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration

Investment Date	Original Shares	Original Value	Current Shares	Current Value	% Return	Split Adjustment	Current price
Jan 03, 2012	1,000.00	$185.33	66.67	$1,852.00	899.28%	0.06667	$27.78

Return calculations do not include reinvested cash dividends.

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Investor Relations Contacts

Investment Calculator

About us

Our Pipeline